Dear <politician_name>,

My name is <first_name> <last_name>.

I am writing to you today as a passionate advocate and as a patient [or parent/family member] affected by NF1 in <electoral_district>.

It is with a sense of urgency and hope that I implore you to take immediate action regarding the Koselugo (selumetinib) file, by urging the pan-Canadian Pharmaceutical Alliance (pCPA) to address it promptly.

NF1 patients with symptomatic and inoperable plexiform neurofibromas currently lack effective treatment options. The absence of therapies for this condition is devastating for individuals and families alike. I respectfully request that you raise your voice to have pCPA expeditiously enter into negotiations with the drug manufacturer, Alexion, to secure timely access to this critical treatment option.

Koselugo has already received approval for its efficacy and has garnered positive recommendations for use in the pediatric population from the Canadian Agency for Drugs and Technologies in Health (CADTH).

This medication holds immense potential to alleviate the tremendous hardships faced by families affected by NF1, offering a glimmer of hope in situations where none existed before.

<supporter_personal_comments>

With Canada's rare disease strategy in place, and a substantial funding of $1.4 billion available, there has never been a better opportunity than now to make a profound impact on families across the nation grappling with this debilitating tumour disorder. By proactively addressing the Koselugo file and securing affordable access to this medication, you have the power to significantly enhance the lives of NF1 patients and their families.

Therefore, I kindly request your immediate attention and swift action in urging pCPA to expedite negotiations with Alexion for Koselugo. As my MLA, I am counting on your leadership and commitment to champion the cause of patients and families impacted by NF1.

Thank you for your time, consideration, and dedication to this crucial matter.

Sincerely,
<full_name>